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Maria J. Nooren, MA,b and Kim G. Smolderen, PhD,a,d Tilburg, The Netherlands; and Kansas City, Mo
Objective: Since it is unknown what factors are weighed in a clinician’s decision to refer patients with symptomatic
lower extremity peripheral arterial disease (PAD) for invasive treatment, we examined the relationship between health
status, lesion location, and site variations and invasive treatment referral #1 year following diagnosis in patients with
PAD.
Methods: This was a prospective observational cohort study on ambulatory patients that presented themselves at two
vascular surgery outpatient clinics. A total of 970 patients with new symptoms of PAD or with an exacerbation of existing
PAD symptoms that required clinical evaluation and treatment (Rutherford Grade I) were eligible, 884 consented and
were included between March 2006 and November 2010. We report on 505 patients in the current study. Prior to
patients’ initial PAD evaluation, the Short Form-12, Physical Component Scale (PCS) was administered to measure
health status. Anatomical lesion location (proximal vs distal) was derived from duplex ultrasounds. PCS scores, lesion
location, and site were evaluated as determinants of receiving invasive (endovascular, surgery) vs noninvasive treatment
#1 year following diagnosis in Poisson regression analyses, adjusting for demographics, ankle-brachial index, and risk
factors.
Results: Invasive treatment as a ﬁrst-choice was offered to 167 (33%) patients. While an association between poorer health
status and invasive therapy was found in unadjusted analyses (relative risk [RR], 0.98; 95% conﬁdence interval [CI], 0.97-
1.00; P [ .011), proximal lesion location (RR, 3.66; 95% CI, 2.70-4.96; P < .0001) and site (RR, 1.69; 95% CI, 1.11-
2.58; P [ .014) were independent predictors of invasive treatment referral in the ﬁnal model.
Conclusions:One-third of patients were treated invasively following PAD diagnosis. Patients’ health status was considered
in providers’ decision to refer patients for invasive treatment, but having a proximal lesion was the strongest predictor.
This study also found some important ﬁrst indications of site variations in offering invasive treatment among patients
with PAD. Future work is needed to further document these variations in care. (J Vasc Surg 2014;59:400-8.)Treatment for symptomatic peripheral arterial disease
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://dx.doi.org/10.1016/j.jvs.2013.08.045of treatments are available for PAD, consisting of strategies
such as supervised exercise therapy, optimal pharmacolog-
ical management, and widely adopted invasive options
like percutaneous transluminal angioplasty (PTA),2-4
current treatment guidelines explicitly state to preferen-
tially treat patients with Rutherford (Grade I) non-
invasively and promote supervised exercise therapy.5-7
Current guidelines additionally mention, however, that
patients’ health status and the anatomic lesion location
they present with are important considerations to take into
account in the clinical decision-making process to refer
patients with PAD for invasive treatment.5-7 In the ﬁeld of
PAD, however, there are virtually no studies available that
examined to what degree these aspects are actually being
weighed in the decision to refer patients for invasive treat-
ment in PAD specialty care and to what degree the
threshold for this decision differs across institutions. In addi-
tion, it remains unclear whether patients in whom we expect
the highest beneﬁt e those with the highest disease burden
e are more likely to receive invasive therapy,4 as compared
with those who are experiencing a minimal disease burden.
To address these gaps in knowledge, this study aimed
to evaluate whether patients’ physical health status, the
anatomic lesion location for which they seek treatment,
as well as the hospital to which patients present, are indeed
important factors in the referral of patients for invasive
treatment for their PAD symptoms. We examined these
Fig 1. Overview of the study population. SF-12, Short Form 12.
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I, who were evaluated for newly diagnosed PAD or for an
exacerbation of existing symptoms of PAD in vascular
specialty clinics. Ideally, we expect that patients who
present with favorable risk-beneﬁt lesions (proximal
lesions) or patients who have a lower physical health status
will be more likely to be referred for invasive treatment as
compared with those having more unfavorable risk-
beneﬁt lesions (distal lesions) or a better health status.2,6,8,9
Addressing these questions seems to be particularly useful
in an era where appropriateness criteria for invasive proce-
dures in PAD are still lacking, and the use of costlyendovascular procedures continue to rise against a back-
ground of tightening budgets for health care.10,11
METHODS
Patients and study design
A total of 1190 patients were screened, 970 were
eligible, 884 consented, and 505 PAD patients were
included (Fig 1 includes an overview of exclusion reasons).
They were consecutively enrolled within an ongoing
prospective observational study for patients who presented
themselves at two vascular surgery outpatient clinics
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The Netherlands) with new onset or an exacerbation of
PAD symptoms that required clinical evaluation. The
cohort under study had 1-year follow-up data available
and was enrolled between March 1, 2006 and November
30, 2010. Inclusion criteria were a resting ankle-brachial
index (ABI) #0.90 or a decrease in postexercise ABI
$15%. Exclusion criteria were a noncompressible ABI
($1.30), critical limb ischemia, severe cognitive impair-
ment, or severe psychiatric or somatic comorbidities (eg,
psychosis or active oncological treatment), insufﬁcient
knowledge of the Dutch language, and other reasons (eg,
treatment for PAD started prior to inclusion in the present
study, participation in another study). Because physical
health status and anatomical lesion location were variables
of interest in this study, participants were additionally
excluded if baseline health status information on the Short
Form 12 (SF-12) had >25% missing values, no preproce-
dural duplex ultrasound examination was available in
patients’ medical records within 3 months prior to or after
enrollment, or they previously underwent lower extremity
bypass surgery. In patients with previous bypass surgery,
categorizations of arterial lesions according to predeﬁned
segments on duplex ultrasound examinations were not
feasible because of changes in patients’ arterial anatomy.12
As these changes do not occur in patients with previous
endarterectomy, those patients were retained in the present
study.
Vascular laboratory assessments were performed as part
of the diagnostic work-up in all participants at baseline
and included ABI assessments at rest and after a treadmill
walking test in both legs, as well as clinical guided
duplex ultrasound examinations. All participants were clini-
cally evaluated by vascular surgeons through a thorough
history-taking and physical examination. Patients completed
an interview and self-report questionnaires at baseline to
document information on demographics, their self-reported
physical health status, and psychological factors. Clinicians
were blinded to the patients’ prospectively collected prepro-
cedural health status scores. Information on risk factors
and medication use was abstracted from patients’ medical
records upon enrollment. Likewise, information on 1-year
treatment practices was retrieved throughout the year
following diagnosis. The study was approved by the local
ethics committee of each participating institution. Written
informed consent was provided by all participants. Since the
study was observational in nature, participation did not
impact the type of treatment patients would receive.
Measures
Treatment strategies. Information on treatment strat-
egies offered during the year following enrollment was
documented through medical chart abstraction. Both
enrolling sites had access to a variety of similar treatment
options including noninvasive options consisting of a formal
supervised exercise therapy program; pharmacotherapy
(eg, aspirin, anticoagulants, and statins); and smoking-
cessation counseling. Patients were considered to havehad noninvasive treatment if no hospital admissions for
vascular reasons in the lower extremities were documented
within the year following enrollment. Lower extremity
invasive treatment strategies included lower extremity
PTA (with or without stents), endarterectomy, and by-
pass surgery. In our analyses, we discriminated between the
ﬁrst-choice treatment that patients were referred to directly
following diagnosis that may have included invasive vs
noninvasive treatment and the ﬁnal treatment that patients
eventually received during the 1-year following enrollment
(to capture information on potential crossovers from
noninvasive to invasive treatment).
Health status. Preprocedural physical health status was
measured by a Dutch language version of the SF-12, a 12-
item generic health status instrument that has been widely
used in cardiovascular populations.2,13 We derived Physical
Component Scale (PCS) scores (mean, 50; standard devia-
tion, 10; range, 0-100) that were standardized against the
general Dutch population norms.14 Higher scores indicated
better physical functioning. Differences of $0.5 standard
deviation ($5 points) are considered clinically relevant.
Duplex ultrasound examination protocol. As part of
the diagnostic evaluation, the treating vascular surgeon
ordered a clinical-guided duplex ultrasound examination,
performed by trained vascular technicians using the Tosh-
iba Xario (Xario XG; Toshiba Medical Systems Europe,
Zoetermeer, The Netherlands) to derive lesion information
(ie, anatomical lesion location, number of lesions, and peak
systolic velocity (PSV [cm/sec]) ratio). A detailed
description of the duplex ultrasound protocol has been
published elsewhere.12
Prior to the study’s statistical analyses, a team of three
physicians (surgical fellow and two vascular surgeons) read
the duplex ultrasounds to categorize the anatomical
location of the peripheral arterial lesions. Duplex readings
performed by this physician panel were executed using the
same protocol as was used at the time of the initial clinical
evaluation. Proximal and distal lesions were scored: prox-
imal lesions included signiﬁcant lesions within the aortoiliac
segments.12 Distal lesions included signiﬁcant lesions within
the femoropopliteal segments and crural segments.12
Lesions with a PSV ratio $2.5 or occlusions were
considered signiﬁcant.12 The combined color and pulsed
wave Doppler has a 87% to 88% sensitivity, and 95% to
99% speciﬁcity for detecting signiﬁcant arterial lesions in
patients with lower extremity PAD as compared with
gold standard angiography in the present literature.15
ABI. Vascular technicians measured patients’ ABI at
rest and following a distance-limited (1000 meters) tread-
mill test to conﬁrm PAD diagnosis using a handheld
Doppler instrument (Imexlab 9000; Imex Medical Systems
Inc, Golden, Colo). From this protocol, patients’ pain-free
walking was also derived. An abnormal ABI was deﬁned as
having a resting ABI of #0.90 or a post-exercise ABI
decrease of $15% as compared with the resting ABI.12
Cardiovascular history, clinical factors, and medi-
cation use. Patients’ medical records were abstracted to
document a cardiac history (angina, myocardial infarction,
JOURNAL OF VASCULAR SURGERY
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intervention, congestive heart failure), cerebrovascular
history (stroke, transient ischemic attack), clinical factors
(current smoking, diabetes mellitus, dyslipidemia, hyper-
tension, body mass index [kg/m2], chronic obstructive
pulmonary disease, renal dysfunction, back pain, knee or
hip osteoarthritis), and history of lower extremity proce-
dures (PTA or endarterectomy). Medical records were also
abstracted to document patients’ medication use following
vascular diagnostic work-up. Claudication medications
(eg, Cilostazol) are not approved or distributed in The
Netherlands, and information on these medications is not
included in this study.
Demographic, socioeconomic, and psychological
factors. Patients’ age and gender was derived from their
medical records; sociodemographic information was ob-
tained by self-report questionnaires and included marital
status (partner vs no partner), educational background
(greater than high school education vs less), and working
status (active vs nonactive). Additionally, the presence of
a distressed (Type D) personality was assessed by the DS14,
an instrument that measures the joint tendency of social
inhibition and negative affectivity. Scores $10 on both
subscales denotes a Type D personality.16 Finally, the
presence of clinically relevant anxiety and depression
symptoms were veriﬁed by the Hospital Anxiety and
Depression Scale (HADS), for which a criterion of scores
$8 was adopted on both subscales.17
Statistical analysis
Baseline patient characteristics were described for the
total population and compared by ﬁrst-choice treatment
strategy (invasive vs noninvasive treatment).
Potential treatment considerations were described by
ﬁrst-choice and ﬁnal treatment strategy (invasive vs nonin-
vasive treatment comparisons for each treatment strategy):
(1) patients’ physical health status (mean PCS scores for
invasive vs noninvasive treatment); (2) the anatomical
lesion location (either proximal or distal lesions or lesions
in both locations); and (3) enrollment site (hospital 1 vs
hospital 2).
For all descriptive comparisons, c2 tests, Student t-tests,
and Wilcoxon rank sum tests were used as appropriate.
Missing SF-12 items were assumed to be missing at
random and handled by multiple imputation (mean of
ﬁve iterations) if $75% of all items were completed by
the participants. A sequential, propensity-weighted Poisson
regression analysis was constructed to examine the associa-
tion between treatment considerations (physical health
status, anatomic lesion location, and hospital site) and
ﬁrst-choice treatment strategy (invasive vs noninvasive
treatment). A propensity weight was calculated based on
all baseline characteristics for the tendency to have missing
PCS data (requiring imputation) vs having complete data
for the PCS. The model was sequentially built using the
following steps: (1) demographic factors (age, gender),
hospital site, and the PCS score; (2) anatomical lesion
location (proximal vs nonproximal); and (3) ABI, priorlower extremity revascularization (PTA or endarterec-
tomy), pain-free walking distance, and cardiovascular risk
factors (cardiac history, cerebrovascular history, diabetes
mellitus, renal failure, current smoking). The analysis was
repeated to determine treatment considerations for the
ﬁnal 1-year treatment strategy (invasive vs noninvasive
treatment). Finally, the area under the receiver operating
characteristics curve was obtained to derive the C-statistics
for both ﬁnal adjusted models.
Analyses were executed with PASW Statistics 17.0 for
Windows (SPSS Inc, Chicago, Ill) and SAS Software
version 9.2 (SAS Institute Inc, Cary, NC). All tests were
two-tailed and P values < .05 were considered statistically
signiﬁcant.
RESULTS
Baseline characteristics. Of the 505 patients included
in the study, 167 (33%) received invasive treatment as ﬁrst-
choice treatment strategy, whereas 338 (67%) were initially
referred to noninvasive treatment.
The Table presents the baseline characteristics of the
total cohort (n ¼ 505) and stratiﬁed by ﬁrst-choice treat-
ment strategy (invasive vs noninvasive). Patients receiving
invasive treatment were more likely to be younger, to
have an active working status, and a lower body mass index
as compared with those receiving noninvasive treatment.
Additionally, they were less likely to receive aspirin upon
PAD diagnosis, and their resting ABI was lower. Patients
who were initially treated invasively were also more likely
to have proximal lesions.
For reasons of completeness, patients’baseline character-
istics were also compared by enrollment site (Supplementary
Tables I and II, online only). No major differences were
noted (effect sizes of observed differences were small: the
range for Cramér’s V was 0.090-0.113 for prior angina,
current smoking, overall anticoagulant use, and aspirin use.
Cohen’s D was 0.21 for pain-free walking distance).
Treatment considerations. Whereas 167 (33%)
patients were initially referred for invasive treatment as a ﬁrst-
choice treatment strategy, ultimately, 198 (40%) patients
were treated invasively, meaning that an additional 31 patients
(6%) received invasive treatment (Supplementary Table III,
online only).
Patients who were referred for invasive options were
more likely to have lower health status scores as compared
with patients who did not undergo invasive treatment as
their ﬁrst-choice treatment (mean PCS scores: 37 6 9 vs
40 6 10; P ¼ .008). The same pattern was observed for
1-year ﬁnal treatment referral (mean PCS scores: 38 6
10 vs 40 6 10; P ¼ .056; Fig 2, a). However, a difference
of <5 points is not considered clinically relevant.
A total of 131 (26%) patients presented with signiﬁcant
proximal lesions, 254 (50%) had signiﬁcant distal lesions,
and 64 (13%) presented with both signiﬁcant proximal
and distal lesions upon diagnosis. A total of 56 patients pre-
sented with nonsigniﬁcant lesions. Patients with proximal
lesions were more likely to be referred for invasive treat-
ment as a ﬁrst-choice treatment as compared with patients
Table. Baseline characteristics of the total sample and stratiﬁed by ﬁrst-choice treatment strategy
Total sample (N ¼ 505)
First-choice treatment strategy
Invasive (n ¼ 167) Noninvasive (n ¼ 338) P value
Demographics
Mean age (range), years 64.7 6 9.7 (37-92) 62.6 6 9.8 65.8 6 9.5 <.0001
Male gender 324 (64.2) 105 (62.9) 219 (64.8) .67
Socioeconomic factors
No partner 123 (24.5) 35 (21.2) 88 (26.0) .24
Less than high school education 127 (25.5) 46 (28.0) 81 (24.2) .35
Working full- or part-time 135 (27.6) 54 (33.3) 81 (24.8) .046
Cardiovascular history
Angina pectoris 69 (13.7) 17 (10.2) 52 (15.4) .11
Myocardial infarction 85 (16.8) 23 (13.8) 62 (18.3) .20
Coronary artery bypass graft surgery 60 (11.9) 15 (9.0) 45 (13.3) .16
Percutaneous coronary intervention 45 (8.9) 12 (7.2) 33 (9.8) .34
Congestive heart failure 20 (4.0) 3 (1.8) 17 (5.0) .08
Stroke 38 (7.5) 14 (8.4) 24 (7.1) .61
Transient ischemic attack 43 (8.5) 10 (6.0) 33 (9.8) .15
Clinical factors
Smoking 250 (49.5) 93 (55.7) 157 (46.4) .05b
Diabetes mellitus 121 (24.0) 38 (22.8) 83 (24.6) .66
Hypercholesterolemia 342 (67.7) 111 (66.5) 231 (68.3) .67
Hypertension 308 (61.0) 95 (56.9) 213 (63.0) .18
Mean BMI 26.7 6 4.6 25.9 6 3.6 27.1 6 5.0 .001
Chronic obstructive pulmonary disease 79 (15.6) 23 (13.8) 56 (16.6) .42
Renal dysfunction 38 (7.5) 10 (6.0) 28 (8.3) .36
Back pain 75 (14.9) 31 (18.6) 44 (13.0) .10
Hip or knee pain 105 (20.8) 39 (23.4) 66 (19.5) .32
Medication use
Overall anticoagulants 447 (88.5) 138 (82.6) 309 (91.4) .004
Aspirin 406 (80.4) 124 (74.3) 282 (83.4) .014
Anticoagulants 82 (16.2) 28 (16.8) 54 (16.0) .82
Statins 416 (82.4) 130 (77.8) 286 (84.6) .06
Beta blocker 210 (41.6) 60 (35.9) 150 (44.4) .07
Diuretics 116 (23.0) 32 (19.2) 84 (24.9) .15
ACE inhibitor 159 (31.5) 54 (32.3) 105 (31.1) .77
Calcium antagonist 106 (21.0) 29 (17.4) 77 (22.8) .16
Nitroglycerine 44 (8.7) 9 (5.4) 35 (10.4) .06
Digoxin 9 (1.8) 2 (1.2) 7 (2.1) .49
Antiarrhythmics 15 (3.0) 5 (3.0) 10 (3.0) .98
Antidepressives 29 (5.7) 13 (7.8) 16 (4.7) .17
Anxiolytics 20 (4.0) 3 (1.8) 17 (5.0) .08
Hypnotics 27 (5.3) 10 (6.0) 17 (5.0) .65
Vascular laboratory assessment
Median pain-free walking distance, m 80.0 6 128.9 70.0 6 131.3 80.0 6 127.6 .14
Mean resting ABIa 0.66 6 0.17 0.63 6 0.17 0.67 6 0.16 .011
Prior lower extremity revascularization
Endovascular 54 (10.7) 24 (14.4) 30 (8.9) .06
Endarterectomy 9 (1.8) 1 (0.6) 8 (2.4) .16
Psychological factors
Depression 143 (28.5) 47 (28.3) 96 (28.7) .94
Anxiety 126 (25.1) 45 (27.1) 81 (24.2) .48
Type D personality 111 (22.1) 42 (25.1) 69 (20.5) .24
ABI, Ankle-brachial index; ACE, angiotensin-converting-enzyme; BMI, body mass index; SD, standard deviation.
Boldface entries indicate statistical signiﬁcance. Continuous data are shown as mean or median 6 standard deviation and categoric data as number (%).
aLowest ABI measured.
bNot signiﬁcant.
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remained the same for the ﬁnal 1-year treatment (76% vs
26%; P < .0001; Fig 2, b). In contrast, ﬁrst-choice as
well as ﬁnal invasive treatment referral was less likely in
patients with distal lesions as compared with those having
no distal lesions (ﬁrst-choice invasive treatment 16% vs51%; P < .0001; 1-year ﬁnal invasive treatment 22% vs
57%; P < .0001). Patients with both proximal and distal
lesions more often received invasive treatment as a ﬁrst-
choice (58% vs 30%; P < .0001) and ﬁnal treatment option
(63% vs 36%; P < .0001) as compared with who were
without lesions in both locations.
Fig 3. Determinants of (a) ﬁrst-choice and (b) ﬁnal treatment strategies (invasive treatment vs noninvasive treatment
options [reference]). The (un)adjusted relative risks (RRs) and 95% conﬁdence intervals (CIs) are presented. The
model was sequentially adjusted for: aPhysical Component Scale (PCS), predicted probability, hospital (site), demo-
graphics (age, gender); banatomical lesion location (proximal vs nonproximal); cankle-brachial index (ABI), prior lower-
extremity revascularization, pain-free walking distance, and cardiovascular risk factors (cardiac history, cerebrovascular
history, diabetes mellitus, renal failure, smoking). dNot signiﬁcant.
Fig 2. Treatment considerations for ﬁrst-choice and ﬁnal treatment strategies. Mean Physical Component Scale (PCS)
scores are presented by ﬁrst-choice and 1-year invasive treatment rates (a); and ﬁrst-choice and 1-year invasive treat-
ment rates are presented by (b) anatomical lesion location,a and (c) hospital site. aPlease note that these comparisons
are based on nonmutual exclusive data (proximal vs nonproximal; distal vs nondistal; both distal and proximal lesions vs
absence of having lesions in both categories).
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hospital site 1 and 37 patients (7%) from hospital site 2.
First-choice and 1-year ﬁnal treatment practices stratiﬁed
by hospital site are presented in Fig 2, c and illustrate
that invasive treatment referral was less common in hospital
1 as compared with hospital 2 (ﬁrst-choice invasive treat-
ment, 32% vs 49%; P ¼ .036; 1-year ﬁnal invasive treat-
ment, 38% vs 56%; P ¼ .055).
Determinants of invasive treatment: Multivariable
results. Multiple imputation was applied in 71 cases to
calculate PCS scores. Patients’ pain-free walking distance
was missing in six cases. There was no other missing co-
variate data.Patients with a better health status were less likely to be
referred for invasive options as ﬁrst-choice treatment as
compared with those having a poorer health status in the
unadjusted model (unadjusted relative risk [RR], 0.98;
95% conﬁdence interval [CI], 0.97-1.00; P ¼ .033) but
was later explained by the presence of proximal lesions
(P < .0001; Fig 3, a). Having a proximal lesion (RR,
4.94; 95% CI, 3.38-7.22; P < .0001) was independently
associated with a higher chance of being referred for ﬁrst-
choice invasive treatment in the ﬁnal adjusted model
(Fig 3, a).
Fig 3, b replicates the results for the 1-year ﬁnal treat-
ment referral, including 493 patients who were alive at
JOURNAL OF VASCULAR SURGERY
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status were less likely to be referred for invasive options
in the unadjusted model (RR, 0.98; 95% CI, 0.97-1.00;
P ¼ .011), as compared with patients who had poorer
health status. Proximal lesion location (RR, 3.66; 95%
CI, 2.70-4.96; P < .0001) and hospital site (RR, 1.69;
95% CI, 1.11-2.58; P ¼ .014) were independently associ-
ated with 1-year invasive treatment referral in the ﬁnal
adjusted model (Fig 3, b). Full model results are presented
in Supplementary Table IV (online only).
The C-statistic was 0.82 (95% CI, 0.79-0.86; P <
.0001) for the ﬁnal model predicting ﬁrst-choice treatment
and 0.82 (95% CI, 0.78-0.86; P < .0001) for the 1-year
model.DISCUSSION
Despite the lack of appropriateness criteria in PAD
management, there seems to be a consensus to preferen-
tially maximizing noninvasive treatment strategies ﬁrst
before offering invasive options for patients with symptom-
atic PAD.5-7 While factors such as response to noninvasive
treatment, anatomical lesion location, quality of life, and
patient preferences may seem to be relevant factors to
take into account when making a decision to refer patients
for invasive treatment,5-7 it is unclear how these factors are
actually being valued in the clinical decision-making
process and whether rates differ with regards to invasive
treatment referrals across hospital sites for patients with
a comparable clinical and symptom proﬁle. The present
study evaluated the association between patients’ physical
health status, anatomical lesion location, and hospital site
and invasive treatment referral in patients with new onset
or an exacerbation of pre-existing PAD symptoms (Ruther-
ford Grade I) at two vascular surgery ofﬁces. Our results
demonstrate that e within the year following their initial
PAD evaluation e more than one-third of the total popu-
lation was referred for invasive options as a ﬁrst-choice
treatment strategy. Invasive treatment was more often
offered to those with a poorer physical health status. Inva-
sive treatment was about four times more applied in
patients having proximal lesions vs distal lesions and nearly
twice as often in one hospital site vs the other. Further-
more, both ﬁnal models reached good discriminative accu-
racy for the prediction of invasive treatment referral.
While prior registries demonstrate that peripheral
revascularizations are major contributors to high hospitali-
zation rates and raising cumulative health care costs,10
there are no studies that systematically evaluate what
factors are weighed in the health care providers’ decision
before referring patients to such costly invasive options.
Likewise, it is unknown whether such decisions and associ-
ated invasive treatment rates vary across institutions.
Recently, such site variations in the intensity of care have
been observed in patients with more advanced stages of
PAD and other vascular conditions, suggesting that it is
worthwhile and much needed to also evaluate treatment
variations in earlier stages of the disease as well.18,19 Whilepreliminary ﬁndings suggest that patients’ self-reported
physical health status matters when choosing an invasive
treatment modality in PAD,9 it is currently unknown
whether favorable risk-beneﬁt lesions (proximal lesions)5-7
and site variations are other important factors that help
clinicians decide to refer patients for invasive options.
Our study is unique because it used clinical data from
two vascular surgery ofﬁces to examine these questions in
a homogenous cohort of ambulatory PAD patients.
According to practice guidelines, invasive treatment as
a ﬁrst-choice option in patients with symptomatic PAD
may be considered in patients presenting with favorable
risk-beneﬁt lesions (proximal disease).5-7 Our ﬁndings
suggest that clinicians are well aware of this evidence and
act accordingly, as patients with proximal lesions were
more likely to be referred for invasive treatment. In addi-
tion, quality of life considerations are another factor that
needs to be considered. Claudication symptoms that are
impairing patients’ daily functioning are important reasons4
to offer an invasive treatment, as higher beneﬁts are ex-
pected in patients whose health status is affected most.
The correlation between poorer health status scores and
receiving invasive treatment may not be perfect, and still
lots of variation is seen in health status scores of those
who are referred for invasive treatment. Hence, further
research and quality of care improvement programs are
needed to ensure that patients who have the highest poten-
tial to improve, based on their poorer health status scores,
are preferentially being considered to undergo invasive
treatment. While we saw a strong association between
lesion location and receipt of invasive treatment, the
observed (un)adjusted associations for health status and
invasive treatment referral were very weak, suggesting
that invasive treatment is not consistently offered in
patients who might need it the most.
In support of this latter hypothesis, we provided e as
one of the ﬁrst in its kind in patients with symptomatic
PAD e preliminary evidence to suggest that variations in
care not only exist based on patient characteristics but are
also explained by practice variations across institutions.
Patients with similar symptoms and clinical proﬁles
(Supplementary Table I, online only) going to one hospital
were almost twice as often invasively treated, as compared
with the other hospital. A long-standing tradition of docu-
menting site variations in care and developing appropriate-
ness criteria for procedures20 has been established in most
cardiac conditions,20-22 but this effort is still in its infancy
for PAD. With the hopes that our study may contribute
to the ﬁeld of quality of care research in PAD, along with
efforts from newer procedural registries (ie, Blue Cross
Blue Shield of Michigan Cardiovascular Consortium
Peripheral Vascular Interventions registry23 or the Society
for Vascular Surgery Vascular Registry24) documenting
the quality of care, future studies need to document proce-
dural variabilities and treatment indications. Finally, the
elements studied in this manuscript should not be the
only driving factors in the decision-making process, but
patient preferences and a discussion about which outcomes
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 2 van Zitteren et al 407are most valued and risks that patients are willing to take
should also be part of the discussion.
Other contextual factors that were not explicitly
studied in this work, but are nevertheless important in opti-
mizing the decision-making process include access to
a variety of treatment options that are promoted in PAD
guidelines and performance measures.5,7,25 For instance,
access to and insurance coverage for supervised exercise
training programs was available to clinicians and patients
at the time of conducting this study in The Netherlands,
but may not be readily available in other countries. Second,
knowledge on what health status outcomes patients can
expect from different treatment modalities given their
personal clinical proﬁle is missing and future comparative
effectiveness research with a focus on health status is war-
ranted in order to provide health care providers and their
patients with sufﬁcient information on treatment risks
and beneﬁts for each alternative treatment option for
lower extremity PAD. Finally, this observational study
cannot exactly reconstruct the actual decision-making
process and considerations that clinicians had when refer-
ring patients to treatment; whether health status was prior-
itized or whether it was patients’ anatomical lesion
information that was a decisive factor or both cannot be
determined. Further qualitative work with both PAD
specialists and patients should give us more insight in the
actual factors that are being considered and into the prior-
itization and weighing of these individual factors.
Some study limitations should be addressed before
interpreting our results. Despite observing site variations,
it should be noted that only two institutions were included
with a difference in sample size. The two study popula-
tions, however, were comparable for baseline characteris-
tics. Furthermore, we were unable to evaluate provider
variability due to the fact that patients may have been
seen by different vascular surgeons and that the enrolling
vascular surgeon was not necessarily the one that referred
patients for their treatment. In addition, patient prefer-
ences regarding the decision to undergo invasive treatment
were not directly measured, and it is unknown how these
may have impacted the decision-making process. Finally,
our results may only be generalizable to the Dutch PAD
population due to differences in reimbursement rates,
access to universal health care, and format for supervised
exercise training facilities.CONCLUSIONS
This study demonstrates that having proximal lesions is
being considered when referring patients for invasive treat-
ment in lower extremity PAD, whereas poorer health status
only marginally explained why clinicians refer patients for
invasive treatment. In contrast, site variability was another
factor that explains variations in referral rates. Against
a background of tightening health care budgets and
a disproportionate high morbidity and economic burden
in patients with PAD,10,26 it is important to continue to
focus on quality of care considerations and developingshared decision-making models to prioritize care to those
patients that need it the most.
The authors would like to thank all participating
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Supplementary Table I (online only). Baseline characteristics stratiﬁed by hospital site
Site 1 (n ¼ 468) Site 2 (n ¼ 37) P value
Demographics
Mean age, years 64.7 6 9.8 65.3 6 8.5 .68
Male gender 298 (63.7) 26 (70.3) .42
Socioeconomic factors
No partner 352 (75.5) 28 (75.7) .99
Less than high school education 117 (25.3) 10 (27.8) .74
Working full- or part-time 127(28.0) 8 (22.9) .51
Cardiovascular history
Angina pectoris 68 (14.5) 1 (2.7) .044
Myocardial infarction 82 (17.5) 3 (8.1) .14
Coronary artery bypass surgery 55 (11.8) 5 (13.5) .79
Percutaneous coronary intervention 43 (9.2) 2 (5.4) .76
Congestive heart failure 18 (3.8) 2 (5.4) .65
Stroke 33 (7.1) 5 (13.5) .18
Transient ischemic attack 40 (8.5) 3 (8.1) 1.00
Clinical factors
Smoking 239 (51.1) 11 (29.7) .012
Diabetes mellitus 111 (23.7) 10 (27.0) .65
Hypercholesterolemia 317 (67.7) 25 (67.6) .98
Hypertension 289 (61.8) 19 (51.4) .21
Mean BMI 26.8 6 4.7 26.3 6 3.7 .46
Chronic obstructive pulmonary disease 73 (15.6) 6 (16.2) .92
Renal dysfunction 34 (7.3) 4 (10.8) .51
Back pain 66 (14.1) 9 (24.3) .09
Hip or knee pain 99 (21.2) 6 (16.2) .48
Medication use
Overall anticoagulants 419 (89.5) 28 (75.7) .011
Aspirin 382 (81.6) 24 (64.9) .013
Anticoagulants 78 (16.7) 4 (10.8) .35
Statins 384 (82.1) 32 (86.5) .50
Beta blocker 196 (41.9) 14 (37.8) .63
Diuretics 107 (22.9) 9 (24.3) .84
ACE inhibitor 147 (31.4) 12 (32.4) .90
Calcium antagonist 99 (21.2) 7 (7.3) .75
Nitroglycerine 42 (9.0) 2 (5.4) .76
Digoxin 9 (1.9) 0 (0.0) 1.00
Antiarrhythmics 12 (2.6) 3 (8.1) .09
Antidepressives 29 (6.2) 0 (0.0) .26
Anxiolytics 19 (4.1) 1 (2.7) 1.00
Hypnotics 27 (5.8) 0 (0.0) .25
Vascular laboratory assessment
Median pain-free walking distance, m 70.0 6 132.0 100.0 6 74.3 .002
Mean resting ABIa 0.66 6 0.16 0.69 6 0.21 .40
Prior lower extremity revascularization
Endovascular 51 (10.9) 3 (8.1) .60
Endarterectomy 8 (1.7) 1 (2.7) .66
Psychological factors
Depression 130 (28.0) 13 (35.1) .36
Anxiety 115 (24.8) 11 (29.7) .51
Type D personality 103 (22.1) 8 (22.2) .98
ABI, Ankle-brachial index; ACE, angiotensin-converting-enzyme; BMI, body mass index; SD, standard deviation.
Boldface entries indicate statistical signiﬁcance. Continuous data are shown as mean or median 6 standard deviation and categoric data as number (%).
aLowest ABI measured.
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Supplementary Table II (online only). Hospital site
characteristics
Site 1
(n ¼ 468)
Site 2
(n ¼ 37)
Number of beds 6 560 6 575
Number of vascular surgeons 4 3
Number of vascular nurse
practitioners
2 0
Academic orientation Nonacademic Nonacademic
Teaching hospital Teaching
hospital
Teaching
hospital
Rural vs urban Urban Urban
Patients with abnormal ABI
from March 1, 2006 to
February 28, 2007
173 49
ABI, Ankle-brachial index.
Supplementary Table III (online only). Treatment
practices of the total sample and stratiﬁed by 1-year
treatment strategya
Total sample
(N ¼ 505),
No. (%)
1-year treatment strategy
Invasive
(n ¼ 198),
No. (%)
Noninvasive
(n ¼ 307),
No. (%)
Lower extremity
revascularization
Endovascular 158 (31.3) 158 (79.8) 0 (0.0)
Surgery 55 (10.9) 55 (27.8) 0 (0.0)
aSince patients may have underwent multiple procedures throughout their
1-year follow-up, numbers will not add up to derive the total number
of patients who underwent invasive procedures.
Supplementary Table IV (online only). Full model results for determinants of treatment strategies (invasive treatment
vs noninvasive treatment options [reference])
First-choice treatment 1-year ﬁnal treatment
RR 95% CI P value RR 95% CI P value
PCS 0.99 0.98-1.01 .37 0.99 0.98-1.01 .23
Predicted probability 0.82 0.16-4.30 .81 0.86 0.22-3.40 .83
Site 1.46 0.87-2.47 .16 1.69 1.11-2.58 .014
Age 1.00 0.98-1.02 .76 1.00 0.98-1.01 .71
Male gender 1.16 0.83-1.64 .39 1.06 0.79-1.41 .71
Proximal lesion 4.94 3.38-7.22 <.0001 3.66 2.70-4.96 <.0001
ABI 1.00 0.99-1.01 .48 1.00 0.99-1.01 .39
Prior revascularizationa 1.17 0.75-1.82 .49 1.16 0.80-1.68 .45
Pain-free walking distance 0.99 0.83-1.18 .89 0.95 0.81-1.12 .55
Cardiac historyb 0.96 0.66-1.41 .85 1.03 0.75-1.41 .88
Cerebrovascular historyc 0.95 0.58-1.55 .84 0.86 0.56-1.31 .47
Chronic obstructive pulmonary disease 0.96 0.60-1.53 .86 0.92 0.61-1.37 .66
Diabetes mellitus 1.19 0.82-1.74 .37 1.08 0.78-1.49 .66
Renal failure 0.92 0.47-1.79 .81 1.14 0.68-1.91 .61
Smoking 1.02 0.72-1.43 .93 0.94 0.71-1.26 .68
ABI, Ankle-brachial index; CI, conﬁdence interval; PCS, Physical Component Scale; PTA, percutaneous transluminal angioplasty; RR, relative risk.
Boldface entries indicate statistical signiﬁcance.
aPrior revascularization includes lower extremity PTA and endarterectomy.
bCardiac history includes: prior angina, myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, and heart failure.
cCerebrovascular history includes prior stroke and transient ischemic attack.
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